Actemra OPTION Trial Shows Benefit In RA Patients In Combination With Methotrexate
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III trial, published in The Lancet, supports the use of Roche’s interleukin-6 inhibitor for rheumatoid arthritis.
You may also be interested in...
Roche’s Actemra Postmarket Safety Plan May Obviate Need For REMS
Roche may have staved off the imposition of a REMS for its rheumatoid arthritis candidate Actemra by proposing a robust pharmacovigilance of its own
Roche’s Actemra Postmarket Safety Plan May Obviate Need For REMS
Roche may have staved off the imposition of a REMS for its rheumatoid arthritis candidate Actemra by proposing a robust pharmacovigilance of its own
FDA Calls Roche’s Arthritis Drug Actemra Effective Ahead Of Panel Meeting
First-in-class interleukin-6 receptor inhibitor may sidestep safety concerns seen with anti-TNFs.